Editorials

Did brentuximab vedotin’s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?

BMT and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
Haematologica Early view Dec 30, 2021 https://doi.org/10.3324/haematol.2021.280284